Telehealth firms start switching patients from compounded copies to branded Zepbound

Telehealth companies Teladoc and LifeMD said on March 6 they signed agreements to sell Eli Lilly's Zepbound to self-paying patients, connecting their weight-loss programs directly to GiftHealth, the pharmacy partner behind Lilly's LillyDirect website ^[1][2]. The deals come as restrictions tighten on compounded copies of tirzepatide, the drug in Zepbound and Mounjaro ^[1].

A federal judge on March 5 denied an injunction that would have let compounding pharmacies keep making copies of Zepbound in the United States ^[1]. That ruling followed the FDA's declaration last month that the shortage of Novo Nordisk's Wegovy and Ozempic was resolved, a decision expected to curb widespread sales of compounded copies of those drugs as well ^[1]. Branded Zepbound and Wegovy had already been removed from the FDA's shortage list ^[1].

The new arrangement gives patients in Teladoc's and LifeMD's virtual weight-loss programs access to Zepbound in doses from 2.5 mg to 15 mg, in both single-vial and single-pen forms ^[2]. Under LillyDirect's self-pay pricing, a 2.5-mg vial costs $349 a month, while 5-mg vials cost $499; higher 7.5-mg and 10-mg doses were also being offered at $499 as of early March, according to the LillyDirect website ^[2]. Teladoc said it does not sell compounded versions and instead prescribes only the branded drug, while LifeMD said it currently offers both compounded and branded options but is prepared to adjust as rules change ^[1].

The scale of the shift is notable. Teladoc has about a million patients enrolled across its chronic-condition management programs, including weight loss, and LifeMD has roughly 75,000 patients that Lilly can now reach directly through the new pharmacy tie-up ^[2]. This follows a similar move by telehealth firm Ro, which began offering single-dose Zepbound vials through LillyDirect in December ^[1][2]. Citi analyst Daniel Grosslight said the agreement signals more deals of this kind are likely as bulk compounding faces sharper limits ^[1].

Why it matters for patients

For people who had been getting cheaper compounded tirzepatide through telehealth platforms, this shift means a move toward paying LillyDirect's self-pay prices for branded Zepbound instead, with monthly costs starting at $349 for the lowest dose and rising to $499 for several higher doses ^[2]. Teladoc's Kelly Bliss said the change is meant to help members